Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine-Reference-Cited by-同舟云学术

Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine

Published:2018-05-24 Issue:7 Volume:14 Page:1800-1806
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Petry Karl-Ulrich¹,Bollaerts Kaatje²,Bonanni Paolo³^ORCID,Stanley Margaret⁴,Drury Rosybel⁵,Joura Elmar⁶,Kjaer Susanne K.⁷,Meijer Chris J. L. M.⁸,Riethmuller Didier⁹,Soubeyrand Benoit⁵,Van Damme Pierre¹⁰,Bosch Xavier¹¹

Affiliation:

1. Department of Gynaecology and Obstetrics, Klinikum Wolfsburg, Germany

2. P95, Epidemiology and Pharmacovigilance, Belgium

3. Department of Health Sciences, University of Florence, Italy

4. Department of Pathology, Cambridge University, United Kingdom

5. MSD, Europe Vaccine Medical Affairs, France

6. Department of Obstetrics and Gynaecology, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Austria

7. Department of Gynaecology, Rigshospitalet, Copenhagen University Hospital and the Danish Cancer Society Research Centre, Copenhagen, Denmark

8. Department of Pathology, Free University Medical Centre, Netherlands

9. Pôle Mère-Femme, University Hospital Jean Minjoz, Besançon, France

10. Centre for Evaluation of Vaccination, Vaccine and Infectious Diseases Institute, University of Antwerp, Belgium

11. Cancer Research Epidemiology Program, Catalan Institute of Oncology, IDIBELL, Spain

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2018.1450125

Reference30 articles.

1. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis

2. The Expected Impact of HPV Vaccination on the Accuracy of Cervical Cancer Screening: The Need for a Paradigm Change

3. Safety and immunogenicity of a 9-valent HPV vaccine in females 12–26 years of age who previously received the quadrivalent HPV vaccine

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Conocimiento del Virus del Papiloma Humano y su vacuna en jóvenes de América Latina. Revisión Sistemática;Kasmera;2024-03-31

2. HPV and Cervical Cancer: A Review of Epidemiology and Screening Uptake in the UK;Pathogens;2023-02-11

3. A Review: Various Challenges and Causes based on Cervical Cancer;2022 5th International Conference on Contemporary Computing and Informatics (IC3I);2022-12-14

4. Myths and fake messages about human papillomavirus (HPV) vaccination: answers from the ESGO Prevention Committee;International Journal of Gynecologic Cancer;2022-07-12

5. Traditional Chinese Medicine in Cancer Care: An Overview of 5834 Randomized Controlled Trials Published in Chinese;Integrative Cancer Therapies;2021-01